Key result
CCR5 antagonists abolish vasoconstriction and reduce neointimal thickening in cultured human saphenous veins.
Why the study?
Does CCR5 antagonism prevent vasoconstriction and intimal hyperplasia in human vessels in vitro?
Population
Human saphenous vein and mammary artery from 104 patients receiving coronary artery bypass grafts, and other…
Comparison
CCR5 antagonists and CCR5 ligands applied in… vs Vehicle control or baseline responses.
Design
Preclinical
Follow-up
14 days (for organ culture)
Authors
Loading...
Supports further study of CCR5 antagonists in vascular remodeling; leaves open clinical translation from in vitro data.
Does CCR5 antagonism prevent vasoconstriction and intimal hyperplasia in human vessels in vitro?
p-value: p=<0.05
CCR5 mediates vasoconstriction and neointimal formation in human vessels in vitro, suggesting that CCR5 antagonists like maraviroc could potentially be repurposed to treat vascular remodeling and vasospasm in cardiovascular disease.
Maguire et al. (2013) studied Atherosclerosis and vein graft disease (n=183). CCR5 antagonists (maraviroc, PF-232796) vs. Vehicle was evaluated on Vasoconstriction and neointimal hyperplasia in vitro (p=<0.05). CCR5 antagonists, including maraviroc, completely abolished CCL4-induced vasoconstriction and significantly inhibited the development of neointimal thickening in cultured human saphenous veins (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: